On Wednesday, Shares of Marathon Oil Corporation (NYSE:MRO), gained 4.34% to $14.65.
Marathon Oil Corporation declared that Lee M. Tillman, Marathon Oil president and CEO, will present at the Barclays CEO Energy-Power Conference in New York on Wednesday, Sept. 9, at 9:45 a.m. EDT.
Marathon Oil Corporation is a global exploration and production company. Based in Houston, Texas, the Company had net proved reserves at the end of 2014 of 2.2 billion barrels of oil equivalent in North America, Europe, and Africa.
Marathon Oil Corporation operates as an energy company. It operates in three segments: North America Exploration and Production, International Exploration and Production, and Oil Sands Mining. The North America Exploration and Production segment explores for, produces, and markets crude oil and condensate, natural gas liquids, and natural gas in North America.
Shares of Canadian Imperial Bank of Commerce (USA) (NYSE:CM), inclined 3.25% to $67.93, during its last trading session.
Canadian Imperial Bank of Commerce (CM), declared its intention to seek Toronto Stock Exchange (TSX) approval for a normal course issuer bid. Purchases of common shares for cancellation will be made subject to CIBC’s ongoing capital requirements. Such purchases will not exceed eight million common shares, or about 2% of its outstanding common shares over a 12-month period.
CIBC will file a notice of intention to make a normal course issuer bid with the TSX and this bid would commence following TSX acceptance of this notice and continue for up to one year.
Purchases would be made through the facilities of the TSX, alternative Canadian trading systems or the New York Stock Exchange, in accordance with applicable regulatory requirements. CIBC intends to periodically establish an automatic program under which its broker, CIBC World Markets Inc., would repurchase CIBC shares following the bid within a defined set of criteria, which CIBC would not vary. The price paid for the common shares will be the market price at the time of the purchase. The common shares repurchased under the normal course issuer bid will be cancelled.
Canadian Imperial Bank of Commerce, a diversified financial institution, provides various financial products and services to individuals and small businesses, and commercial, corporate, and institutional clients in Canada and internationally.
Finally, Kite Pharma Inc (NASDAQ:KITE), ended its last trade with 2.98% gain, and closed at $51.53.
Kite Pharma, stated financial results for the quarter ended June 30, 2015.
Highlights of Developments in Second Quarter 2015
- Commenced Kite’s Phase 1/2 clinical trial of KTE-C19, an anti-CD19 CAR T-cell therapy, for treatment of refractory, aggressive Non-Hodgkin’s Lymphoma (NHL).
- Presented clinical biomarker results at the 2015 American Society of Clinical Oncology Annual Meeting, which demonstrated that conditioning chemotherapy was associated with a noteworthyrise in homeostatic cytokines and chemokines, which could favor expansion, activation, and trafficking of CAR T cells.
- Declared our first TCR product candidate, targeting HPV-16 E6 that we plan to advance to a company-sponsored clinical trial.
- Reached an exclusive worldwide partnership with bluebird bio to advance second-generation TCR products to treat HPV-associated cancers.
- Partnered with The Leukemia & Lymphoma Society to enhance the development of KTE-C19 in refractory, aggressive NHL and to launch CAR T-cell therapy educational programs.
- Accomplished construction of our clinical supply manufacturing facility in Santa Monica, California.
- Began construction on our manufacturing facility in El Segundo, California to support our commercial plans.
- Hosted our first Investor Day, which focused on our future research, clinical, and manufacturing plans.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
